American Capital Management Inc. Sells 35,824 Shares of ResMed Inc. (NYSE:RMD)

American Capital Management Inc. trimmed its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 7.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 459,070 shares of the medical equipment provider's stock after selling 35,824 shares during the quarter. ResMed comprises about 3.7% of American Capital Management Inc.'s investment portfolio, making the stock its 8th largest holding. American Capital Management Inc. owned approximately 0.31% of ResMed worth $112,068,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Versor Investments LP grew its holdings in shares of ResMed by 327.3% during the 2nd quarter. Versor Investments LP now owns 4,700 shares of the medical equipment provider's stock worth $900,000 after purchasing an additional 3,600 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in ResMed by 245.2% during the second quarter. Assenagon Asset Management S.A. now owns 33,507 shares of the medical equipment provider's stock worth $6,414,000 after buying an additional 23,801 shares in the last quarter. Addenda Capital Inc. grew its stake in ResMed by 17.4% during the second quarter. Addenda Capital Inc. now owns 58,986 shares of the medical equipment provider's stock worth $11,291,000 after buying an additional 8,747 shares in the last quarter. Retireful LLC bought a new position in ResMed in the 3rd quarter valued at about $742,000. Finally, Asset Management One Co. Ltd. raised its position in shares of ResMed by 5.1% in the 3rd quarter. Asset Management One Co. Ltd. now owns 58,860 shares of the medical equipment provider's stock valued at $14,369,000 after buying an additional 2,878 shares in the last quarter. Institutional investors own 54.98% of the company's stock.

Insider Buying and Selling at ResMed

In related news, insider Justin Leong sold 6,160 shares of the business's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the transaction, the insider now owns 21,718 shares in the company, valued at $5,279,428.62. The trade was a 22.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Witte Jan De sold 796 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the sale, the director now directly owns 6,723 shares in the company, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 68,334 shares of company stock worth $16,379,713. Insiders own 0.71% of the company's stock.

ResMed Trading Down 0.1 %

NYSE RMD traded down $0.31 during trading hours on Friday, reaching $249.02. The company's stock had a trading volume of 351,327 shares, compared to its average volume of 842,042. The firm has a fifty day simple moving average of $242.24 and a 200-day simple moving average of $225.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. ResMed Inc. has a 52 week low of $156.39 and a 52 week high of $260.49. The stock has a market cap of $36.56 billion, a P/E ratio of 32.98, a P/E/G ratio of 1.81 and a beta of 0.69.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the firm earned $1.64 earnings per share. The company's revenue for the quarter was up 11.1% on a year-over-year basis. Equities analysts forecast that ResMed Inc. will post 9.28 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Thursday, November 7th. ResMed's payout ratio is presently 28.08%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on RMD shares. Royal Bank of Canada increased their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a research report on Friday, October 25th. Bank of America raised their target price on ResMed from $240.00 to $270.00 and gave the company a "buy" rating in a report on Thursday, September 26th. Robert W. Baird lifted their price target on ResMed from $280.00 to $283.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. Wolfe Research restated an "underperform" rating and set a $180.00 price objective on shares of ResMed in a research report on Wednesday, September 18th. Finally, Baird R W upgraded ResMed to a "strong-buy" rating in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $225.70.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.